ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer
10.3969/j.issn.1672-7347.2013.12.004
- VernacularTitle:三磷酸腺苷-肿瘤体外药敏试验对宫颈癌临床化学治疗的指导作用
- Author:
Ying ZHANG
;
Qian ZHAO
;
Yanan JIANG
;
Zhongfu YUAN
;
Li YANG
- Publication Type:Journal Article
- Keywords:
cervical cancer;
ATP-tumor chemosensitivity assay;
chemotherapy regimen
- From:
Journal of Central South University(Medical Sciences)
2013;38(12):1223-1227
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay.
Methods:Seventy-two hospitalized patients with cervical cancer between July 2007 and October 2009 were enrolled. The patients were randomly divided into a trial group (n=35) and a control group(n=37). ATP-TCA was used to detect the sensitivity of 35 samples of cervical cancer in the trial group to 6 combined chemotherapy regimens. The chemotherapy regimen in the trial group was confirmed by the results of susceptibility testing and that in the control group was confirmed by clinical experience. One-year recurrence rate and 3-year survival rate of two groups were compared after 3 year follow-up.
Results:ATP-TCA was measured in 32 of the 35 patients in the trial group. The sensitive patients for paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, and gemcitabine+cisplatin were 20, 18, 17, 18, 17, and 21, respectively. There was no significant difference in the 1-year recurrence between the two groups (P>0.05), while the 3-year survivors in the trial group were more than those in the control group (P<0.05).
Conclusion:ATP-TCA method is good for patients with cervical cancer because it is sensitive, effective, and individualized.
